Elham Aflaki

Elham Aflaki

Auto-generated profile, based on publicly available information

Elham Aflaki

Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
Ahmad GholamiAhmad Gholami
Ahmad Gholami
JAJassem Azizpoor
Jassem Azizpoor
EAElham Aflaki
Elham Aflaki
MRMehdi Rezaee
Mehdi Rezaee
KKKhosro Keshavarz
Khosro Keshavarz
Introduction. Rheumatoid arthritis (RA) is a chronic progressive inflammatory disease that causes joint destruction. The condition imposes a significant economic burden on patients and societies. The present study is aimed at evaluating the cost‐effectiveness of Infliximab, Adalimumab, and Etanercept in treating rheumatoid arthritis in Iran. Methods. This is a cost‐effectiveness study of economic evaluation in which the Markov model was used. The study was carried out on 154 patients with rheumatoid arthritis in Fars province taking Infliximab, Adalimumab, and Etanercept. The patients were selected through sampling. In this study, the cost data were collected from a community perspective, and the outcomes were the mean reductions in DAS‐28 and QALY. The cost data collection form and the EQ‐5D questionnaire were also used to collect the required data. The results were presented in the form of an incremental cost‐effectiveness ratio, and the sensitivity analysis was used to measure the robustness of the study results. The TreeAge Pro and Excel softwares were used to analyze the collected data. Results. The results showed that the mean costs and the QALY rates in the Infliximab, Adalimumab, and Etanercept arms were $ 79,518.33 and 12.34, $ 91,695.59 and 13.25, and $ 87,440.92 and 11.79, respectively. The one‐way sensitivity analysis confirmed the robustness of the results. In addition, the results of the probabilistic sensitivity analysis (PSA) indicated that on the cost‐effectiveness acceptability curve, Infliximab was in the acceptance area and below the threshold in 77% of simulations. The scatter plot was in the mentioned area in 81% and 91% of simulations compared with Adalimumab and Etanercept, respectively, implying lower costs and higher effectiveness than the other two alternatives. Therefore, the strategy was more cost‐effective. Conclusion. According to the results of this study, Infliximab was more cost‐effective than the other two medications. Therefore, it is recommended that physicians use this medication as the priority in treating rheumatoid arthritis. It is also suggested that health policymakers consider the present study results in preparing treatment guidelines for RA.

22 February 2020 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Open access
PDF file
MYMohammad-Reza Yazdani
Mohammad-Reza Yazdani
EAElham Aflaki
Elham Aflaki
NGNasser Gholijani
Nasser Gholijani
The cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus erythematosus (SLE) patients. Malar rash and discoid lupus (DLE) are in the category of acute and chronic CLE, respectively. The pathogenesis of CLE is multifactorial, and cytokine imbalances contribute to immune dysfunction and the induction of organ damage. Many aspects of cytokine dysregulation are still unclear in SLE and in particular CLE. Therefore, we concurrently measured the inflammatory [Tumor necrosis factor-alpha (TNF-α) and Interleukin (IL)-6)], T helper (Th)-17 (IL-17 and IL-23) and regulatory T cells [Transforming growth factor-beta (TGFβ) and IL-10)]-related cytokines in patients with CLE (patients with malar rash and/or DLE) and compared them with SLE patients and healthy individuals (n=25 in each group, a total of 75 patients). The serum levels of cytokines were assessed by Enzyme-Linked Immunosorbent Assay (ELISA) method. IL-6 cytokine was significantly higher in SLE, DLE, and malar rash patients compared to those in healthy controls (p=0.025) and in patients with arthralgia (p=0.038), and gastrointestinal involvement (p=0.048). IL-17 was significantly higher in malar rash patients compared to normal individuals (p=0.023), SLE (p=0.008) and DLE patients (p=0.019) and in patients with oropharyngeal ulcer (p=0.05) but, IL-23 was significantly higher only in DLE patients than healthy controls (p=0.019). In conclusion, inflammatory cytokines such as IL-6 involved in inflammation and differentiation of Th17 cells are probably responsible in part for Th17 activity in CLE. IL-17, IL-23, and IL-6/IL-6R (IL-6 receptor) inhibitors may be good treatments for CLE patients. So targeting these cytokines activity pathways can improve the CLE treatment strategy and may open a novel guideline for SLE and CLE treatment.

16 May 2023 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
KAKourosh Ahmadi
Kourosh Ahmadi
EAElham Aflaki
Elham Aflaki
MJMojgan Akbarzade Jahromi
Mojgan Akbarzade Jahromi
LDLadan Dastgheib
Ladan Dastgheib

1 March 2024 in Journal of Occupational Health and Epidemiology
Verified
Journal Article
Open access
HAHabibollah Azarbakhsh
Habibollah Azarbakhsh
EAElham Aflaki
Elham Aflaki
JHJafar Hassanzadeh
Jafar Hassanzadeh
EPElahe Piraee
Elahe Piraee
AMAta Miyar
Ata Miyar
RMReza Mirahmadizadeh
Reza Mirahmadizadeh

5 April 2024 in Rheumatology
Verified
Journal Article
Open access
SSSaeedeh Shenavandeh
Saeedeh Shenavandeh
EAElham Aflaki
Elham Aflaki
MRMaryam Rasti RastiJahromi
Maryam Rasti RastiJahromi
AHAfshin Borhani Haghighi
Afshin Borhani Haghighi
MNmohammadali nazarinia
mohammadali nazarinia
Introduction: The treatment of Behçet’s disease has improved significantly with the introduction of biologic therapies. However, there is still a need for more information about their use. This study aimed to evaluate the indications, response, and side effects of biologic agents in patients...

18 September 2025 in The Egyptian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
FSFaezeh Sehatpour
Faezeh Sehatpour
EAElham Aflaki
Elham Aflaki
Backgrounds: Cytokine storm has been considered a major pathogenic in severe COVID-19 patients with severe disease. Inflammatory cytokines, such as interleukin-6(IL-6), IL-1, and tumor necrosis factor alpha (TNF-α) released from the lung epithelium during COVID-19 infection resemble those involved in inflammatory rheumatic diseases. Immunosuppressive drugs are central in managing any rheumatologic diseases. Immunosuppressive drugs are central in managing any rheumatologic diseases, and prolonged use may alter clinical features of COVID-19 in these patients. Objective: To determine the clinical findings and disease severity of COVID-19 infection in patients with rheumatic diseases under immunosuppressive therapy. Method: A retrospective case–control study of 981 patients with rheumatic diseases attending university—affiliated clinics and hospital in Shiraz, Iran, including 539 patients with confirmed COVID-19 infection and 442 COVID-19—negative controls without documented infection. Results: Pre-exposure to prednisolone was associated with increased severity of COVID-19 (adjusted OR 2.52; 95% CI 1.19–4.26). Methotrexate (MTX) use was associated with milder disease (OR 0.35; 95% CI 0.21–0.58). Among biologic therapies, anti-TNF agents (etanercept, infliximab) users showed a significant association with lower severity (OR 0.33; 95% CI 0.16–0.69), whereas the smaller rituximab (anti-CD20) subgroup (n = 54) was insufficiently powered for separate analysis. Other conventional DMARDs showed no significant effect. Hydroxychloroquine did not show protective effects. Conclusion: In this cohort of Iranian patients with rheumatic diseases, prior corticosteroid use was associated with increased COVID-19 incidence and severity, whereas MTX and anti-TNF biologics were associated with milder disease outcomes. Due to sample size limitations and contrasting literature on rituximab (anti-CD20), we caution against generalizing protective effects across all biologics. Our findings suggest that immunosuppressive therapy influences COVID-19 outcomes, but prospective studies are needed to elucidate mechanisms and causality.